Objective:
To evaluate the efficacy of migaldendranib in reducing injection frequency and improving retinal structure and visual function in patients with DME and nAMD.
Key Findings:
- Annualized injection rates decreased from 8.4 to 1.6 in study eyes and from 8.3 to 0.9 in fellow eyes, representing reductions of nearly 80% and 90%, respectively.
- Participants gained an average of 6.1 ETDRS letters in visual acuity for DME eyes.
- Reductions in central subfield thickness were observed in both DME and nAMD eyes.
- No treatment-related systemic or ocular serious adverse events were reported.
Interpretation:
Migaldendranib may offer a less burdensome alternative to frequent intravitreal injections, with significant improvements in visual function and retinal anatomy.
Limitations:
- Further studies are needed to confirm safety and efficacy before regulatory approval.
Conclusion:
Migaldendranib shows promise in treating DME and nAMD with reduced injection frequency and improved visual outcomes.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.